Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Radiofrequency Ablation For Recurrent Parathyroid Carcinoma

NCT: NCT07475780 · RECRUITING

NCT IDNCT07475780
StatusRECRUITING
Start Date2026-04-09
Completion2031-04-30

Brief Summary

The study will be an effectiveness study. The study will include enrollment of a total of 20 patients with at least one PC lesion for ultrasound guided RFA to PC recurrence in the neck to assess the effectiveness in reducing patient's hypercalcemia. Patients will have surgically proven PC from prior parathyroidectomy and suspicious PC visible on ultrasound and request for treatment for uncontrolled hypercalcemia (Figure 1).

Frequently Asked Questions

What is Radiofrequency Ablation For Recurrent Parathyroid Carcinoma?

Radiofrequency Ablation For Recurrent Parathyroid Carcinoma is a clinical trial registered under NCT07475780. Current status: RECRUITING.

What is the status of NCT07475780?

The current status of NCT07475780 (Radiofrequency Ablation For Recurrent Parathyroid Carcinoma) is: RECRUITING.

When did Radiofrequency Ablation For Recurrent Parathyroid Carcinoma start?

Radiofrequency Ablation For Recurrent Parathyroid Carcinoma started on 2026-04-09.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.